Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

reement-for-investigational-anti-cancer-drug-pci-32765">December 2011 to co-develop and co-commercialize ibrutinib.

About PharmacyclicsPharmacyclics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to, generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MINNEAPOLIS, Jan. 19, 2012 Zyga Technology, Inc. announced ... the company and will serve as Vice President of ... (Logo: http://photos.prnewswire.com/prnh/20110118/CG30384LOGO ) Joe ... Medical Device Industry.  He began his career at Codman ...
... Berkery Noyes, an independent middle market investment bank, today ... trend report for the Pharma & Healthcare ... report analyzes the sector for 2011 and compares it ... includes information and technology companies servicing pharmaceutical, healthcare payer, ...
Cached Medicine Technology:Zyga Technology, Inc. Makes Two Key Additions to the Sales Leadership Team 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 3
(Date:7/25/2014)... The new report “Carbohydrase Market by Applications (Food ... Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, ... Forecasts to 2019", by MarketsandMarkets, identifies the driving ... with analysis of trends, opportunities, winning imperatives, and ... forecasted on the basis of major regions such ...
(Date:7/25/2014)... In today’s technological era, every organization is dependable on ... the organization in various ways. But there is high ... the confidential information and processes of the organization. ... and protect the enterprise from various types of threats ... to the comp may. The equipment's of the EGRC ...
(Date:7/25/2014)... 25, 2014 The Rottenstein Law ... with over 25 years of experience advocating for ... prescription drugs, announces the launch of its new ... those who believe they have been harmed by ... offers valuable information about the severe adverse side ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines and segments ... of revenue. The liquid chromatography reagents market in Europe ... is estimated to grow to around $1581.8 million by ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. This also provides a ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Unlike children, the vast majority ... their plate at mealtime, according to a new study. ... world -- not just Americans, researchers from Cornell University revealed. ... lose weight or improve their eating habits make better choices. ... into your stomach," researcher Brian Wansink, director of the ...
Breaking Medicine News(10 mins):Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Most Adults Are Members of 'Clean Plate Club' 2
... belief that adolescent boys tend to take romance for a ... to heart matters, they might not be so fleeting after ... outside, an adolescent boy fails to communicate his emotions, leading ... ,Boys are more vulnerable and emotionally engaged in romantic ...
... at the University of California, appearing in the latest ... says that people// with autism never "daydream" The researchers ... of people having autism and those not affected by ... the brain, emotions and thoughts are processed. However this ...
... India Institute of Medical Sciences (AIIMS) here is running short ... than sanctioned//, Rajya Sabha was informed Friday. ,Replying to ... Panabaka Lakshmi said that the AIIMS was running with just ... ,She also informed the house that during 2003-05, ...
... Economy Research Institute at the University of Massachusetts listed ... air pollution//. This list is officially called the Toxic ... source of air pollution. This is based on air ... the United States. , The various factors ...
... in Australia's medical schools have become so inadequate that ... parts even confusing// certain vital organs with each other. ... have raised concerns that medical students are not being ... the students are not properly trained in anatomy. According ...
... of Medical Sciences (RIMS) is organising a three-day intensive ... states from today// the 11th April. This course is ... the shortfall of sports medicine specialists in the Northeast; ... ,Professor L Fimate the RIMS director, while addressing ...
Cached Medicine News:Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3
The Shandon Citadel is a low cost, reliable, time-tested carousel-type tissue processor with convenient touch key operation. The Citadel 2000 has 110 cassette capacity and the Citadel 1000 has a cap...
... Senior Grossing Wokrstation is a durable, ... for gross examination and sectioning of ... 3 efficient ventilation systems and options ... water faucets, table rinses, disposals and ...
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... Gross-Star Grossing Workbench is a durable, ... gross examination and sectioning of specimens. ... ventilation with a choice of 3 ... for cold/hot water faucet, optional formalin ...
Medicine Products: